Stock profile
AstraZeneca PLC
AZN.LSE
LSE
GBX
ISIN GB0009895292
Market tone: Positive sentiment score 0.97 from 1 mentions, latest 28 Mar 2026.
Open 13,862.00p
Prev close 13,910.00p
Volume 285,504
Frequency
Semi-annual
1.8 events/year
Trend
Falling
2022-2026 payout trend
Volatility
13.96%
annual payout CV
Growth
-7.90%
annualised payout
Recent Dividends
Dividend£1.68Final
Event yield1.40% - 1.45%declared to ex-div
Ex-div drop-0.97%price move
Decl06 Feb
Ex-div20 Feb
Pay24 Mar
Dividend76.7pInterim
Event yield0.64% - 0.79%declared to ex-div
Ex-div drop-0.94%price move
Decl06 Feb
Ex-div07 Aug
Pay08 Sep
Dividend£1.60Final
Event yield1.03% - 1.13%declared to ex-div
Ex-div drop-1.62%price move
Decl10 Feb
Ex-div19 Feb
Pay23 Mar
Price History
05 Dec 2024 to 24 Jun 2026
9,197.00
10,900.75
12,604.50
14,308.25
16,012.00
Jan 25
Apr 25
Jul 25
Oct 25
Jan 26
Apr 26
Decl 06 Feb
Ex 20 Feb
Pay 24 Mar
Decl 06 Feb
Ex 07 Aug
Pay 08 Sep
Decl 10 Feb
Ex 19 Feb
Pay 23 Mar
£1.68 Final
- Declared
- 06 Feb
- Ex-div
- 20 Feb
- Yield
- 1.40%–1.45%
- Ex-drop
- -0.97%
- Paid
- 24 Mar
76.7p Interim
- Declared
- 06 Feb
- Ex-div
- 07 Aug
- Yield
- 0.64%–0.79%
- Ex-drop
- -0.94%
- Paid
- 08 Sep
£1.60 Final
- Declared
- 10 Feb
- Ex-div
- 19 Feb
- Yield
- 1.03%–1.13%
- Ex-drop
- -1.62%
- Paid
- 23 Mar
News
EODHD feed
24 Jun 2026
Positive 0.99
Can AstraZeneca PLC (AZN) Grow Its Rare Disease Portfolio Through Ultomiris Expansion?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. AstraZeneca PLC (NYSE:AZN) is one of the best weight loss drugs on this list.
TheFly reported on
24 Jun 2026
Positive 0.98
YMCA of the USA Announces Plan to Expand Cancer Programs Nationwide with Multimillion Dollar AstraZeneca Partnership
YMCA of the USA
CHICAGO, June 24, 2026 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA) announced a plan to expand and enhance its ability to support people on their cancer journey thr
24 Jun 2026
Negative -1.00
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities
WILMINGTON, Del., June 24, 2026--(BUSINESS WI
24 Jun 2026
Positive 1.00
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
AIM ImmunoTech Inc.
Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transform
24 Jun 2026
Positive 0.99
CelLBxHealth PLC (ANPCF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships and ...
This article first appeared on GuruFocus.
Release Date: June 22, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positi
23 Jun 2026
Positive 1.00
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
Historically known for its innovative biologic medicines such as Enbrel, Prolia and Repatha, Amgen AMGN has also emerged as one of the global leaders in biosimilars. The company bo
Historical Dividends
Total dividends and yield-at-ex-date by year
Payout trend
4.88%
Growing · 2021-2025 payout CAGR
Payout volatility
6.40%
Stable · std dev / average payout
Peak payout£2.45
Peak annual yield2.64%
2021
25 Feb £1.37
12 Aug 64.8p
2022
24 Feb £1.45
11 Aug 76.4p
2023
23 Feb £1.63
10 Aug 71.8p
2024
22 Feb £1.56
08 Aug 77.6p
2025
20 Feb £1.68
07 Aug 76.7p
2026
This year
19 Feb £1.60
07 Aug 76.8p
2027
Projection
19 Feb £1.58
07 Aug 76.8p
| Year | Ex-date | Declared | Record | Payment | Period | Value |
|---|---|---|---|---|---|---|
| 2026 | 19 Feb 2026 | 10 Feb 2026 | - | 23 Mar 2026 | Final | 1.5950 GBP |
| 2025 | 07 Aug 2025 | 06 Feb 2025 | - | 08 Sep 2025 | Interim | 0.7670 GBP |
| 2025 | 20 Feb 2025 | 06 Feb 2025 | - | 24 Mar 2025 | Final | 1.6800 GBP |
| 2024 | 08 Aug 2024 | 21 Feb 2024 | 08 Aug 2024 | 09 Sep 2024 | Interim | 0.7760 GBP |
| 2024 | 22 Feb 2024 | 08 Feb 2024 | 22 Feb 2024 | 25 Mar 2024 | Final | 1.5600 GBP |
| 2023 | 10 Aug 2023 | 09 Feb 2023 | 10 Aug 2023 | 11 Sep 2023 | Interim | 0.7180 GBP |
| 2023 | 23 Feb 2023 | 09 Feb 2023 | 23 Feb 2023 | 27 Mar 2023 | Final | 1.6280 GBP |
| 2022 | 11 Aug 2022 | 10 Feb 2022 | 11 Aug 2022 | 12 Sep 2022 | Interim | 0.7640 GBP |
| 2022 | 24 Feb 2022 | 10 Feb 2022 | 24 Feb 2022 | 28 Mar 2022 | Interim | 1.4530 GBP |
| 2021 | 12 Aug 2021 | 11 Feb 2021 | 12 Aug 2021 | 13 Sep 2021 | Interim | 0.6480 GBP |
| 2021 | 25 Feb 2021 | 05 Nov 2020 | 25 Feb 2021 | 29 Mar 2021 | Interim | 1.3740 GBP |
| 2020 | 13 Aug 2020 | 24 Oct 2019 | 13 Aug 2020 | 14 Sep 2020 | Interim | 0.6960 GBP |
| 2020 | 27 Feb 2020 | 24 Oct 2019 | 27 Feb 2020 | 30 Mar 2020 | Interim | 1.4640 GBP |
| 2019 | 08 Aug 2019 | 08 Nov 2018 | 08 Aug 2019 | 09 Sep 2019 | Interim | 0.7190 GBP |
Upcoming Dividends
Declared and projected dividend cycle| Ex-date | Status | Period | Dividend | Est. yield |
|---|---|---|---|---|
| 07 Aug 2026 | Predicted | Interim | 0.7680 GBP | 0.55% |
| 19 Feb 2027 | Predicted | Final | 1.5840 GBP | 1.14% |
Recovery Signature
Post ex-div behaviourMedian recovery1dtrading days to regain pre-ex close
Recovered83.33%events recovered inside 6w
Drop capture85.25%ex-drop as share of dividend paid
Score82speed, consistency, and drift blend
Bold white line = average visible recovery curve
6 events selected